0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
2003 Views 
0 Saved
0 Vote 1 Contributor2003 Views 0 SavedYou might also be interested in
It might depend on the cancer. Stage I breast cancer is the earliest stage of invasive breast cancer. At this stage, the cancer cells have spread beyond the original location and into the surrounding breast tissue. Because a stage I tumor is small, it may be difficult to detect. However, breast s....
Yes, but indirectly. Free radicals can damage DNA but the cells have their own reparative mechanisms. For free radicals to cause cancer, the following events need to happen:- 1. Damage in individual cells significant enough to overwhelm its reparative mechanisms. 2. Damage in such a way that even ....
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.